FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

REXULTI® (brexpiprazole) agitation that may happen with dementia due to Alzheimer's disease

Rexulti治療失智症躁動怎麼用？第一個美國FDA認可治療阿茲海默失智症躁動(agitation)症狀的藥物- 大腦森林閱讀之旅

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

Articles about Otsuka America Pharmaceutical, Inc.

FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms

Otsuka and Lundbeck Receive the US FDA's Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer's Disease

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Medicare coverage debates amplify as FDA approves Rexulti for Alzheimer's agitation

FDA Approves the First Drug for Alzheimer's Agitation: Rexulti

Memory Care-FDA Approves Drug to Treat Alzheimer's Agitation

FDA approves first drug to treat agitation associated with dementia due to Alzheimer's

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation

FDA advisors to weigh use of Rexulti for Alzheimer's agitation